229 related articles for article (PubMed ID: 34785349)
1. Phosphodiesterase 4 inhibitors in diabetic nephropathy.
Ookawara M; Nio Y
Cell Signal; 2022 Feb; 90():110185. PubMed ID: 34785349
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of a novel phosphodiesterase 4 selective inhibitor, compound A, in diabetic nephropathy model mice.
Ookawara M; Nio Y; Yamasaki M; Kuniyeda K; Hanauer G; Tohyama K; Hazama M; Matsuo T
Eur J Pharmacol; 2021 Mar; 894():173852. PubMed ID: 33422506
[TBL] [Abstract][Full Text] [Related]
3. Targeting phosphodiesterase 4 as a therapeutic strategy for cognitive improvement.
Wei X; Yu G; Shen H; Luo Y; Shang T; Shen R; Xi M; Sun H
Bioorg Chem; 2023 Jan; 130():106278. PubMed ID: 36413930
[TBL] [Abstract][Full Text] [Related]
4. Advances in the development of phosphodiesterase-4 inhibitors.
Li G; He D; Cai X; Guan W; Zhang Y; Wu JQ; Yao H
Eur J Med Chem; 2023 Mar; 250():115195. PubMed ID: 36809706
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.
Bhat A; Ray B; Mahalakshmi AM; Tuladhar S; Nandakumar DN; Srinivasan M; Essa MM; Chidambaram SB; Guillemin GJ; Sakharkar MK
Pharmacol Res; 2020 Oct; 160():105078. PubMed ID: 32673703
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
Page CP; Spina D
Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
[TBL] [Abstract][Full Text] [Related]
7. TAS-203, an oral phosphodiesterase 4 inhibitor, exerts anti-inflammatory activities in a rat airway inflammation model.
Demizu S; Asaka N; Kawahara H; Sasaki E
Eur J Pharmacol; 2019 Apr; 849():22-29. PubMed ID: 30716315
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
9. Advances in the Development of Phosphodiesterase-4 Inhibitors.
Peng T; Qi B; He J; Ke H; Shi J
J Med Chem; 2020 Oct; 63(19):10594-10617. PubMed ID: 32255344
[TBL] [Abstract][Full Text] [Related]
10. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
11. Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor.
Keravis T; Monneaux F; Yougbaré I; Gazi L; Bourguignon JJ; Muller S; Lugnier C
PLoS One; 2012; 7(1):e28899. PubMed ID: 22247763
[TBL] [Abstract][Full Text] [Related]
12. PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes.
Jin J; Mazzacuva F; Crocetti L; Giovannoni MP; Cilibrizzi A
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511275
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2.
Ikari J; Michalski JM; Iwasawa S; Gunji Y; Nogel S; Park JH; Nelson AJ; Farid M; Wang X; Schulte N; Basma H; Toews ML; Feghali-Bostwick C; Tenor H; Liu X; Rennard SI
Am J Respir Cell Mol Biol; 2013 Oct; 49(4):571-81. PubMed ID: 23656623
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase-4 Inhibition in Parkinson's Disease: Molecular Insights and Therapeutic Potential.
Roy D; Balasubramanian S; Krishnamurthy PT; Sola P; Rymbai E
Cell Mol Neurobiol; 2023 Aug; 43(6):2713-2741. PubMed ID: 37074485
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.
Dong C; Virtucio C; Zemska O; Baltazar G; Zhou Y; Baia D; Jones-Iatauro S; Sexton H; Martin S; Dee J; Mak Y; Meewan M; Rock F; Akama T; Jarnagin K
J Pharmacol Exp Ther; 2016 Sep; 358(3):413-22. PubMed ID: 27353073
[TBL] [Abstract][Full Text] [Related]
16. Characterization of LY2775240, a selective phosphodiesterase-4 inhibitor, in nonclinical models and in healthy subjects.
Patel DR; Urva S; Ho S; Buckman CJ; Ma Y; Lim J; Sissons SE; Zuniga MS; Philips D; Cox K; Dairaghi DJ
Clin Transl Sci; 2021 May; 14(3):1037-1048. PubMed ID: 33382916
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 4 and its inhibitors in inflammatory diseases.
Jin SL; Ding SL; Lin SC
Chang Gung Med J; 2012; 35(3):197-210. PubMed ID: 22735051
[TBL] [Abstract][Full Text] [Related]
18. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
Schafer PH; Parton A; Capone L; Cedzik D; Brady H; Evans JF; Man HW; Muller GW; Stirling DI; Chopra R
Cell Signal; 2014 Sep; 26(9):2016-29. PubMed ID: 24882690
[TBL] [Abstract][Full Text] [Related]
19. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis.
Bäumer W; Hoppmann J; Rundfeldt C; Kietzmann M
Inflamm Allergy Drug Targets; 2007 Mar; 6(1):17-26. PubMed ID: 17352685
[TBL] [Abstract][Full Text] [Related]
20. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases.
Abbott-Banner KH; Page CP
Basic Clin Pharmacol Toxicol; 2014 May; 114(5):365-76. PubMed ID: 24517491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
